The term of office for the IRCM's President and Scientific Director, Tarik Möröy, is extended until 2019

The term of office for the IRCM's President and Scientific Director, Tarik Möröy, is extended until 2019. (CNW Group/Institut de recherches cliniques de Montréal (IRCM))

MONTREAL, June 13, 2014 /CNW Telbec/ - This week, the Board of Directors at the IRCM (Institut de recherches cliniques de Montréal) unanimously approved the extension of Dr. Tarik Möröy's term of office as the institute's President and Scientific Director until March 2019. His current term was set to end in 2016.

Dr. Möröy's accomplishments since taking office include the establishment of harmonious and constructive institutional relationships with various research centres, ministries and other agencies that interact with the IRCM, particularly the Université de Montréal; the recruitment of successful young researchers; an upholding of the quality of research; and a major commitment to the development of the clinic and translational research.

"Dr. Möröy has the Board's full support for the continuance of his term," says Louise Lambert-Lagacé, Chairwoman of the Board. "I wish to thank him for the outstanding work he has done so far and I trust that we can expect more great things to come."

About Tarik Möröy
Tarik Möröy is the IRCM's fourth President and Scientific Director. Dr. Möröy is also Director of the Hematopoiesis and Cancer research unit, and holds the Canada Research Chair (Tier 1) in hematopoiesis and immune cell differentiation. He is Full IRCM Research Professor and full research professor in the Department of Microbiology and Immunology (with an accreditation in biochemistry) at the Université de Montréal. Dr. Möröy is also adjunct professor in the Department of Medicine (Division of Experimental Medicine) and the Department of Biochemistry at McGill University. Since 1991, over 20 graduate students have acquired their PhD or Master's degree under his mentorship.

Tarik Möröy holds a PhD (1987) in biochemistry from the Ludwig-Maximilians University in Munich, Germany. Among other administrative positions, Dr. Möröy was Executive Director of the Institute for cell biology and Chairman of the Board at the Center for Medical Biotechnology at the Duisburg-Essen University. In addition, Dr. Möröy directed many federally- and EU-funded research consortia in Germany and sat on several scientific advisory boards. For more information about the IRCM's President and Scientific Director, visit www.ircm.qc.ca/IRCM/president.

About the IRCM
Founded in 1967, the IRCM (www.ircm.qc.ca) is currently comprised of 35 research units in various fields, namely immunity and viral infections, cardiovascular and metabolic diseases, cancer and genetic diseases, neurobiology and development, systems biology and medicinal chemistry. It also houses four specialized research clinics, eight core facilities and three research platforms with state-of-the-art equipment. The IRCM employs 425 people and is an independent institution affiliated with the Université de Montréal. The IRCM Clinic is associated to the Centre hospitalier de l'Université de Montréal (CHUM). The IRCM also maintains a long-standing association with McGill University. The IRCM is funded by the Quebec ministry of Economy, Innovation and Export Trade (Ministère de l'Économie, de l'Innovation et des Exportations).

SOURCE Institut de recherches cliniques de Montréal (IRCM)

Image with caption: "The term of office for the IRCM's President and Scientific Director, Tarik Möröy, is extended until 2019. (CNW Group/Institut de recherches cliniques de Montréal (IRCM))". Image available at: http://photos.newswire.ca/images/download/20140613_C9971_PHOTO_EN_41396.jpg

For further information:

Lucette Thériault
Communications Director (IRCM)
(514) 987-5535 |  lucette.theriault@ircm.qc.ca